OSI Pharmaceuticals Announces Tarceva Granted First European Approval

OSI Pharmaceuticals announced that the Swiss health authority, Swissmedic, has approved Tarceva (erlotinib) for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen. Tarceva is an oral tablet indicated for daily administration. Tarceva is the only drug in the epidermal growth factor receptor (EGFR) class to demonstrate in a Phase III clinical trial an increase in survival in advanced NSCLC patients.

BioSpace (http://www.biospace.com/news_story.cfm?StoryId=19456120)